Skip to main content

Table 5 Primary (mean change in HbA1c from baseline at study end) and key secondary outcomes of the SURPASS 1–5 clinical trials with the obtained results

From: Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Study name

Primary/secondary endpoint(s) (weeks)

Mean HbA1c at baseline (%)

Mean HbA1c reduction from baseline (%) with tirzepatide 5/10/15 mg

Percentage of patients who met +HbA1c < 7.0%; #HbA1c ≤ 6.5% and *HbA1c < 5.7% with tirzepatide 5/10/15 mg

Mean body weight at baseline (kg)

Mean reduction in body weight from baseline (kg) with tirzepatide 5/10/15 mg

Percentage of patients who met a weight loss of a≥ 5%; b≥ 10%; and c≥ 15% with tirzepatide 5/10/15 mg

SURPASS-1

[38]

40

7.94

1.87/1.89/2.07

+87/92/88

#82/81/86

*34/31/52

85.9

7.0/7.8/9.5

a67/78/77

b31/40 /47

c13/17/27

SURPASS-2

[39]

40

8.28

2.01/2.24/2.30

+82/86/86

#69/77/80

*27/40/46

93.7

7.6/9.3/11.2

a65/76/80

b34/47/57

c15/24/36

SURPASS-3

[40]

52

8.17

1.93/2.20/2.37

+82/90/93

#71/80/85

*26/39/48

94.3

7.5/10.7/12.9

a66/84/88

b37/56/69

c13/28/43

SURPASS-4

[41]

52

8.52

2.24/2.43/2.58

+81/88/91

#66/76/81

*23/33/43

90.3

7.1/9.5/11.7

a63/78/85

b36/53/66

c14/24/37

SURPASS-5

[42]

40

8.31

2.11/2.40/2.34

+87/90/85

#74/86/80

*24/42/50

95.2

5.4/7.5/8.8

a56/68/85

b24/49/48

c8/28/27

  1. Results of the SURPASS-6 trial are not yet available